A number of studies revealed that overweight is a key risk factor of nonalcoholic fatty liver disease (NAFLD), which can induce liver chronic inflammation and injury, subsequently, leading to mild to moderately asymptomatic elevation of abnormal liver enzyme levels, particularly ALT and aspartate aminotransferase (AST) [42, 43, 44]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.